Skip to content

Earnings call

Lupin Q4 FY25 earnings call: Lupin’s fiscal year ‘26 is going to be a material year on the injectables front

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

Fiscal year ‘26 is going to be a material year on the injectables front. The company had 12 plants serving the US market, but 11 were serving it at the time because the Pune biotech facility was yet to be approved by the FDA. The company had USD 2.7 billion in revenue and USD 625 million in EBITDA in FY2025. The company expects to garner the insulin market share vacated by Novo, particularly in cartridges, and expects Huminsulin® market share to increase by another 6-7% from its current 18%. The company was the 12th largest generic company by revenues.

The numbers management gave

Results

  • The company had USD 2.7 billion in revenue and USD 625 million in EBITDA in FY2025.
    Show source
    We had a great year with USD 2.7 billion in revenue and USD 625 million in EBITDA, delivered by a very strong group of Lupin ytts.
  • The company evolved its EBITDA margins on a consistent basis over the last 10 to 12 quarters as its US business turnaround enabled consistent and profitable growth.
    Show source
    On the commercial front, the turnaround of the US business was a material event for us over the last couple of years that enabled us to get back to consistent growth and more importantly profitable growth for the organization, and evolve our EBITDA margins on a consistent basis over the last 10 to 12 quarters.
  • Chronic share in India increased from sub 60% five years ago to 64% today.
    Show source
    Our chronic share was sub 60% Today, it's 64% chronic, so more sustainable, more profitable business.
  • GIB business had a 20% CAGR in the last five years, with growth led by scaling up TB, including tuberculosis prevention products like Rifapentine, and building out the HIV portfolio.
    Show source
    Page 13 of 31 May 15, 2025 Lastly, our GIB business actually had one of the best CAGR’s across our businesses, 20% in the last five years.
  • The company Diagnostics had 44% year-on-year revenue growth.
    Show source
    On Lupin Diagnostics, 44% year -on-year revenue growth.
  • Complex generics grew from 2% of its US business in FY20 to 34% in FY25.
    Show source
    So if you see the US, FY20 complex generics was 2% of the business, grew to 34% in FY25.
Show 16 more statements

Results

  • OTIF levels are 100%.
    Show source
    If you look at from a customer focus perspective, our OTIF levels are at 100%..
  • OTIF level in India is 98%.
    Show source
    Even for India, 98%.
  • The company delivered USD 50 million in savings last year through AVDs, freight optimization, yield improvement and similar measures.
    Show source
    USD 50 million were delivered last year through AVDs, through freight optimization, yield improvement and the like.
  • EBITDA margin was 23.2% in the quarter ended March 31, 2025, after an INR 100 crore increase in R&D expenditure and a decline of about INR 50 odd crores in PLI claimed for the quarter.
    Show source
    The first is, essentially, you would see a INR 100 crore increase when it comes to the R&D expenditure and there has been a decline in terms of PLI that we claimed for this quarter, which is about INR 50 odd crores.
  • EBITDA margin in the quarter ended March 31, 2025 would have been close to 26% after adjusting for the INR 100 crore increase in R&D expenditure and the decline of about INR 50 odd crores in PLI claimed for the quarter.
    Show source
    So if you would adjust for these two, the actual EBITDA margin would have been close to about 26%.
  • Adjacencies that started in recent times are still making a loss; including those losses would add another 3.7 percentage points to the EBITDA margin calculation.
    Show source
    If you were to Page 17 of 31 May 15, 2025 take that into account, that would actually be good another 3.7 % points.
  • Full-year EBITDA margin was 23.7% in FY25, compared with about 19% last year.
    Show source
    Full year FY25, we are moving it at 23.7%.
  • The company had a pipeline of about 109 molecules but was not getting approvals to launch them, so its top line was not moving.
    Show source
    So whilst we had a pipeline of close to about 109 molecules, we unfortunately were not getting the approvals to launch them and to that extent, the top line was not moving .
  • The company undertook a mission to reduce costs by about INR 750 to INR 1,000 crores.
    Show source
    We also undertook a mission to actually bring down cost by close to about, INR 750 to INR 1,000 crores.
  • Other operating expenses were about 30.4% in FY20; measures taken since then brought these lines below 30%.
    Show source
    Page 18 of 31 May 15, 2025 But since then, a lot of the measures that we took have brought these lines back to less than 30%, something that we committed to the investing community some time ago.
  • R&D spend has been kept constant at about 8% of sales as it focuses on more complex products.
    Show source
    A lot of emphasis on moving to more complex products and though of course the R&D spends have been increasing as a percentage of sales , it has actually been kept constant around, about 8%.
  • PLI impact was about 1% lower this quarter because it capped out at the annual claim limit, while higher R&D spending also affected the margin; without those impacts, the 23.2% margin would potentially have been 26%.
    Show source
    If we knock out that impact, then potentially that 23.2% would have been 26%.
  • MDI and DPI business in the US accounted for one-third of its US portfolio from a revenue perspective.
    Show source
    It took us long, 5 years from filing to get FDA approval but it's enabled us to build Respiratory as a major vertical for our business in the US When I look at our MDI and DPI business in the US, right now it's one-third of our US portfolio from a revenue’s perspective.
  • Air-ocean ratio is at an all-time low, with only new product launches generally sent by air and everything else mostly sent by ocean.
    Show source
    Our air ocean ratio is down to an all-time low.
  • The company lost exclusivity on a couple of diabetes products in India, while the overall respiratory market did not perform too well.
    Show source
    India, this particular quarter, it was seemingly lacklustre but the fact of the matter is we lost exclusivity on a couple of products when it came to diabetes.
  • Last seven to eight quarters were a period of continuous growth. Replaced by a later filing.
    Show source
    So the last seven to eight quarters have been a period of continuous growth.

What it expects ahead

What management expects

  • Fiscal year ‘26 is going to be a material year on the injectables front.
    Show source
    When you look at our major pillars of our business, the US in particular has come a long way for the organization, evolving our portfolio from the simple products to complex generics, in particular on the inhalation front, very soon on the injectable front as well, fiscal year ‘26 is going to be a material year on the injectables front, and biosimilars, which is an opportunity that is emerging now for us.
  • Tolvaptan is going to be a material contributor to Lupin in fiscal year ‘26.
    Show source
    We also continue to operate our legacy business of oral solids, ophthalmic, dermatology, and leverage product opportunities that differentiate us, like you have seen Mirabegron, Tolvaptan that is going to be a material contributor in fiscal year ‘26.
  • The company would like to grow 1.2, 1.3 times the market in India and has done that in many years.
    Show source
    We'd like to grow 1.2, 1.3 times the market and we have done that in many years.
  • Complex generics will grow to 55% of its US business over the next five years.
    Show source
    And if you see again the next five years, will grow to 55% of the business in the US.
  • Complex Generics will contribute 55% of Lupin's new product revenues in FY27, 54% in FY28, 61% in FY29 and 62% in FY30.
    Show source
    But FY27, you see a very large portion, 55% coming from Complex Generics.
  • The company expects products such as Tolvaptan and continued growth in Spiriva® to offset declines in other products and help it grow over USD 250 million a quarter.
    Show source
    So, we expect some products to go down and products like Tolvaptan and continued growth in Spiriva® would offset some of the decline in other products and helps us hopefully grow over USD 250 million a quarter.
Show 27 more statements

What management expects

  • The company expects its R&D spend to grow by at least about 10% to 15% next year, principally because it is working on more complex products.
    Show source
    I expect at least about 10% to 15% growth out there.
  • R&D spend is about 8% of sales right now and is expected to be upward of 8.5% next year.
    Show source
    So, I believe that will be upward of 8.5% next year.
  • The company can bring Enbrel® into the US market itself in fiscal year 30 and expects it to be a material opportunity because it will likely be one of four in the marketplace.
    Show source
    It will be a material opportunity for us because we likely will still be one of four in the marketplace.
  • In the last 12 months, Lupin has seen an opportunity to enter the biosimilars market directly in the US, particularly for products like Pegfilgrastim.
    Show source
    In the last 12 months with the changes in the US we really see an opportunity of going direct into the market with biosimilars .
  • The company expects to grow at double digit, with the intent to grow 20-30% ahead of a market it believes will grow at 6-7% or 8%, as the case may be.
    Show source
    I think the intent is to grow at 20 -30% ahead of the market, I believe the market will grow at 6 -7% or 8% as the case maybe.
  • The company could emerge as a very large insulin player, particularly if it can bring access to tier 2 - tier 3 towns.
    Show source
    And to add to that I think Rajeev talked about the insulin, I think the insulin opportunity, I think we can emerge as a very large insulin player as Lupin and specially if we can bring access to tier 2 - tier 3 towns I think the opportunity is a very large opportunity in itself.
  • The company expects to grow its margins over the next 3 to 5 years while affording investment, as R&D spend on complex generics and new product launches of complex generics increase over the next 5 years.
    Show source
    So, we should be able to afford the investment and still grow our margins.
  • The company is looking at point-of-sales expansion and new product launches across multiple therapy areas in Brazil.
    Show source
    We're looking at point -of-sales expansion and we are looking at new product launches across multiple therapy areas in Brazil.
  • The company Diagnostics’ target is to be EBITDA positive in FY27.
    Show source
    The target is to be EBITDA positive in FY27.
  • The company aspires to more than double Lupin Life, its OTC business, in the next three to four years.
    Show source
    The aspiration is to well more than double this in the next three to four years.
  • The company expects inhalation products to come to market in FY29 and expects to get steady on the injectable side in FY29.
    Show source
    And in FY29, you see a whole slew of inhalation products that will come to market and that's I think, when we will get steady on the injectable side as well.
  • The company expects its margins to go up by at least about a percentage point this year, as in the past.
    Show source
    This year, of course, we think it will go up by at least about percentage point as in the past.
  • The company expects its margins to continue going up as its pipeline evolves and its adjacencies grow to critical mass and start contributing profits.
    Show source
    And if that were to be brought in, you would certainly expect the margins to creep up.
  • The company expects pressure on Albuterol and has already started seeing it.
    Show source
    We think that you know we are going to see pressure on Albuterol, we have already started seeing it.
  • The company expects Tolvaptan to be a great contributor in the first half of this fiscal year, but expects to give up share in the second half as other competitors enter, despite its first-mover advantage in a specialty drug that is a REMS product.
    Show source
    But second half we certainly expect other competitors to come in and while our first mover advantage will be there because it is a specialty drug, it is a REM S product we will expect to give up share.
  • The company expects to get approval for Glucagon between July and August.
    Show source
    It is between July and August that we should get approval.
  • The company expects Risperidone to be approved in the next couple of months.
    Show source
    We haven’t heard any different on Risperidone, in the next couple of months we should get that approved as well.
  • The company has relationships with ophthalmic distributors and may enter the market for Ranibizumab and Aflibercept if it gets approval in time and can launch the products.
    Show source
    So, we have the relationships in place to be able to enter that market if we get approval in time and can launch the product.
  • Development costs and market-access costs for products using private labels have come down, and Lupin plans to leverage its development and manufacturing capabilities to pursue products where it is in the first wave or among the few in the marketplace.
    Show source
    If you have a private label avenue, like Cordavis, the CVS private label or one of the other private labels where you are not creating the commercial infrastructure, we already have the capabilities on the development and manufacturing front, why would we not leverage it to get products where we are in the first wave or products where we are one of the few in the market place.
  • The company may bring in a private equity player or strategic partner for its adjacencies to help them grow, while their evolution, growth and profitability remain important but are not the most critical factors for margin expansion.
    Show source
    At some point of time we would also perhaps look at allowing them to spin on their axis by getting a private equity player or a strategic end to kind of allow them to grow also.
  • The company is conducting a study to bring NaMuscla® to the US, where the opportunity is multiple times that of the current product.
    Show source
    And CNS neurology - with NaMuscla®, we are now doing the study to bring the product to US as well, that’s multiple times the opportunity of the current product.
  • The company sees other neurology products as synergistic with its infrastructure in Europe and the infrastructure it will build in the US.
    Show source
    If we can g et other neurology products, they will be synergistic with the infrastructure that we have in Europe as well as what we will build in the US.
  • Trade generics subsidiary is expected to grow at a strong number, and OTC is expected to grow at a very strong double-digit number.
    Show source
    OTC is expected to grow at a very strong double-digit number as well.
  • Internal product for Canada will come later; Lupin does not have the product in Canada as of yet and its team is actively looking at an in-licensing opportunity.
    Show source
    The team is actively looking at an opportunity of in-licensing but we have an internal product which will come later into Canada.
  • Medium-term plan calls for double-digit growth on the diabetes side.
    Show source
    But I think we are talking many years out , certainly our MTP is talking about the double -digit growth on the diabetes side as well.
  • The company will continue to evolve its CDMO business based on its API capabilities to build value with this vertical. Replaced by a later filing.
    Show source
    This past year, we have made significant progress there in terms of the teams and capabilities and we will continue to evolve our CDMO business based on these API capabilities to be able to build value with this vertical.
  • The company plans to sustain growth in its two major regions, India and the US, and is confident of continuing to grow in both regions in the foreseeable future based on its portfolio and planned investments. Replaced by a later filing.
    Show source
    And based on the portfolio we have, based on the investments that we plan to make, we are confident of continuing to grow in both regions in the foreseeable future.

What it is building and selling

Projects and capacity

  • The company had 12 plants serving the US market, but 11 were serving it at the time because the Pune biotech facility was yet to be approved by the FDA.
    Show source
    I'd say 11 right now because the Pune biotech facility is yet to be approved by the FDA, but have multiple manufacturing sites that are approved by the FDA, as well as other regulators that enable us to build our generic business.
  • Annual capital expenditure averaged about INR 500 to INR 700 crores over 4-5 years, with a larger chunk for maintenance and some expansion, especially in biosimilars and injectables.
    Show source
    And that I think average is about INR 500 to INR 700 crores.
  • The company Manufacturing Solutions has an R&D center in Pune.
    Show source
    And we have an R&D center in Pune.
  • The company is investing in the Ellipta Line and the Respimat Line at Coral Springs.
    Show source
    Our own investments in Coral Springs , we are investing into the E llipta Line, we are investing into the Respimat Line - that was already under way even before this administration.
  • The company would be open to setting up more US manufacturing and doing more US development if incentives or grants are offered, and is in active dialogue on the matter.
    Show source
    And if there are incentives offered, grants offered to set up more manufacturing, do more development in the US, we certainly be open to it.
  • The company is continuing to invest in its respiratory franchise. Replaced by a later filing.
    Show source
    So, we are continuing to invest in the respiratory franchise.
Show 31 more statements

Demand and pricing

  • The company expects to garner the insulin market share vacated by Novo, particularly in cartridges, and expects Huminsulin® market share to increase by another 6-7% from its current 18%.
    Show source
    We expect with this space becoming available we will be able to garner another 6-7% market share as far as Huminsulin® is concerned.
  • The company was still the only generic in the marketplace for Spiriva®.
    Show source
    We are still the only generic in the marketplace.
  • The company expects the Semaglutide market to grow as lower prices increase usage.
    Show source
    And we expect that this market is going to go up because once the prices come down the usage is going to go up.
  • One or two filers have already filed for competition to Spiriva®.
    Show source
    Vinita Gupta: There are one or two filers that have filed already.

Segments

  • The company was the 12th largest generic company by revenues.
    Show source
    When you look at our company globally, we are the 12th largest generic company by revenues.
  • The company was the 3rd largest company in the US by prescriptions dispensed.
    Show source
    Starting with the US, where we are the 3rd largest company by prescriptions dispensed.
  • The company was the 8th largest company in India, primarily organically.
    Show source
    India, where we are the 8th largest, primarily organically.
  • The company was the 4th largest company on the generic front in Australia and the 8th largest company on the generic front in South Africa.
    Show source
    And other markets like Australia, where we are the 4th largest company on the generic front, and South Africa, where we are the 8th largest company on the generic front.
  • US and Other Developed Markets were roughly 50% of its business, and India and Other Emerging markets were roughly 50%.
    Show source
    The US and Other Developed Markets are roughly 50%, India and Other Emerging markets are roughly 50%.
  • The company received approval for Spiriva® in 2023 and launched it as a sole generic, becoming the first Indian company to launch a DPI in the US.
    Show source
    On the complex generic front, we were the first Indian company to launch a DPI in the US We were very proud with Spiriva® to be able to get that approval in 2023 and launch it as a sole generic.
  • The company expanded its position in India with 11 new divisions and increased its field force from 5,000 five years ago to 10,000 plus, enabling growth above the market growth rate in the country.
    Show source
    In India, we have expanded our position with 11 new divisions, a field force up from, it was 5,000, I think, 5 years ago, to 10,000 plus at this point, so significant expansion that has enabled us to grow above the market growth rate in the country.
  • 40% of Lupin’s portfolio in Brazil was OTC.
    Show source
    40% of our portfolio in Brazil is OTC.
  • The company Life Sciences, Lupin's trade generics business, launched last year and has more than 400 people in its field force, focused primarily on tier two and tier three towns and areas where Lupin is currently under-prescribed.
    Show source
    The focus is primarily on tier two and tier three towns and areas where we're currently under-prescribed and we are building a lot of on-the-ground presence with more than 400 people in that field force, which is different from the model which many other people do it.
  • The company is pursuing 30-plus First to Files.
    Show source
    Right now, we're pursuing 30-plus First to Files, as I mentioned.
  • The company has 12 inhalation products in the market across geographies, over 10 injectable products, Etanercept as its only biosimilar at this point, and well over 300 oral solids products over time.
    Show source
    So again, , in inhalation, 12 products in the market across geographies, injectable, over 10 products, biosimilars, obviously Etanercept only at this point of time and the oral solids, obviously well over 300 products over time.
  • The company has 30 inhalation products in its pipeline, another 30 injectable products in its pipeline, and over 10 biosimilar products in its pipeline.
    Show source
    And you see the products in the pipeline, and inhalation, that's where we are all in, 30 products in the pipeline.
  • The company received approvals for Albuterol in 2021, when its actual business movement started.
    Show source
    The actual movement started in 2021 when we got our approvals for Albuterol and since then, the mojo was back.
  • The company brought Posaconazole and a couple of other products to market in 2022.
    Show source
    In 2022, we actually brought in a couple of other products also Posaconazole was one of the products.
  • The company is developing Semaglutide in-house and has partnered with other partners to develop it ahead of its going off-patent in March 2026.
    Show source
    Semaglutide going off-patent as Vinita also mentioned in March 2026, we are developing in-house also Semaglutide and we have partnered with other partners also so we are very much ready once it goes LOE.
  • About 70%-72% of Lupin's R&D spend today is on complex products, including biosimilars, the inhalation portfolio, complex injectables, 505(b)(2)s and, in some parts, specialty.
    Show source
    If we take count actually close to about 70%- 72% of our spends today is really on complex stuff.
  • Inhalers account for roughly 30% of Lupin's R&D expenditure.
    Show source
    Ramesh Swaminathan: Yeah, I would say roughly about that.
  • India and Emerging Market business was primarily branded, while its US and Other Developed Market business was primarily generic.
    Show source
    And when you look at the nature of the business, the India and Emerging Market is primarily branded business.
  • Complex generics are the largest part of growth in Other Developed Markets, especially Europe, Canada, and Australia.
    Show source
    Other Developed Markets, especially Europe, Canada, Australia, leveraging our portfolio in the US, the platforms in the US, complex generics are the largest part of growth in Other Developed Markets and allow us to really build both on our capacities, manufacturing as well as R&D capabilities, to gain operating leverage across the globe.
  • The company is not present in North India and is present across most other geographies in India.
    Show source
    We're not in North India.
  • The company Manufacturing Solutions is Lupin's CDMO business.
    Show source
    And the last of the adjacencies, Lupin Manufacturing Solutions, our CDMO business.
  • Additional API capacity, resulting from its prior overinvestment in API, has become a large opportunity amid China-related rhetoric and customers seeking alternatives.
    Show source
    But I think you know with some of the China rhetoric, with some of the alternatives that people have been seeking as well I think it has become a large opportunity.
  • CRDMO business is fully functional as a separate entity with a separate office, and its revenues are expected to reach a meaningful number in the next two years.
    Show source
    I think the revenues it will be nothing meaningful at this point of time, I think in the next two years it will get to a meaningful number.
  • Specialty areas of focus are Respiratory and CNS.
    Show source
    Page 26 of 31 May 15, 2025 Vinita Gupta: So, on the areas of focus, they are very much Respiratory and CNS.
  • The company Manufacturing Solutions has a global team and its structures in place. Replaced by a later filing.
    Show source
    We have a full Global team, all the structures in place.

Deals and partners

  • AmerisourceBergen, now Cencora, accounts for 70% of the ophthalmic market and visits 70% of the ophthalmic clinics.
    Show source
    AmerisourceBergen which is now Cencora is 70% of the ophthalmic market, they visit 70% of the ophthalmic clinics.
  • The company has mitigated biosimilar risks through partnerships on development costs and commercialization.
    Show source
    We have tried to mitigate the risks through partnerships, partnerships on the development cost, partnerships on commercialization.

Risks, rules and outside factors

Risks and disputes

  • The company continues to sell Mirabegron with no change and believes it has plenty of defences and a good chance to fight at trial in February.
    Show source
    And we have the trial in February, and believe that we have plenty of defences that, you know we have a good chance to fight at that point in time.

Outside factors

  • The company is working to reduce supply-chain risk from China and other single-source entities by building agility into the system to improve lead times.
    Show source
    Whether it's from China or whether it's other single source entities, we are working to build agility into the system so that our lead times just keep getting better and better.

Rules and policy

  • The FDA reduced the requirements for interchangeability studies, and the private label model appeared in the US, making the US an attractive biosimilars market for selective portfolio choices.
    Show source
    There's been a lot of back and forth on the biosimilars front over the last couple of years, but given the change from a regulatory perspective, Page 3 of 31 May 15, 2025 the FDA reducing the requirements for interchangeability studies, as well as the private label model appearing in the US, the US is emerging as an attractive biosimilars market, of course with selective portfolio choices.
  • The company says the MFN policy would impact the brand side of its business much more than the generic side.
    Show source
    Vinita Gupta: I think the MFN would definitely impact the brand side of the business much more than the generic and the focus under IRA has been on the highest value drugs.

Everything else said on the call

What management stressed

  • The company says it needs to build capability in commercial capability and project management for its CDMO opportunity.
    Show source
    I think our key goal was commercial capability and project management.
  • Generic business has potential to gain efficiency in commercial execution and operations, optimize costs, and improve quality through AI. Replaced by a later filing.
    Show source
    On the generic side of the business as well, there are multiple areas where we have potential gains here, from an efficiency standpoint, commercial execution standpoint, operation standpoint, cost optimization as well as quality perspective - that our industry is going to leverage.
  • The company is focusing on products with a limited number of competitors or where it can be one of few in the marketplace as barriers to entry reduce. Replaced by a later filing.
    Show source
    So, the focus is on products where the number of competitors are limited or where we can be one of few in the market place.

Group structure

  • The company acquired Huminsulin® to penetrate Tier-2 and Tier-3 markets and capture the insulin market there.
    Show source
    Rajeev Sibal: So as far as the Lily acquisition is concerned our objective was to acquire Huminsulin® so we can penetrate into Tier-2 Tier-3 markets also and we can capture that market of insulin there.
  • The company recently spun out its trade generics business into a wholly-owned subsidiary to focus on driving that business.
    Show source
    We have continued to focus on commercial excellence in areas that we felt needed dedicated focus, like the trade generics business that we recently spun out into a wholly-owned subsidiary, with the idea of really focusing hard on driving that business given the growth of the trade generics business in India, and Lupin Manufacturing Solutions, which again as I mentioned in the previous slide, on the API front, allows us to leverage our capabilities on the API R&D and manufacturing to build a CDMO business.
  • Xopenex® in the US enabled Lupin to enter the brand side of the business.
    Show source
    Xopenex® in the US enabled us to get into the brand side of the business.
Show 1 more statement

Group structure

  • The company acquired Xopenex® when Sunovion was looking to exit the market, as a strategic opportunity to enter the brand business on the respiratory front.
    Show source
    When Sunovion was looking to get out of the market, we thought it was a strategic opportunity for us to have a foot into the brand business on the respiratory front in particular.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

This transcript does not separate questions and answers, so they are not listed here.

Questions about this call

When was the Lupin Q4 FY25 earnings call transcript filed?
Lupin filed the transcript with the exchange on 21 May 2025. This page is built from that transcript.
What does this page list?
103 statements from the transcript across 11 topics, 53 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
No. This transcript does not separate the questions from the answers, so they are not listed. The statements by topic still cover what management said.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Lupin Q4 FY25 concall: Lupin’s fiscal year ‘26 is going to be a material year on the injectables front · DalalOS